Illumina (ILMN) Osake Kurssi

Illumina Inc is primarily active in the biotechnology industry.

The main competitors of Illumina Inc in the market include companies like Thermo Fisher Scientific, Pacific Biosciences, and Oxford Nanopore Technologies.

Illumina Inc. is a renowned genomics company with a rich history and background. Founded in 1998, Illumina has consistently been at the forefront of genomic research and has played a vital role in advancing the field of genetic sequencing. The company specializes in developing innovative technologies and solutions for genetic variation analysis, DNA sequencing, and genotyping. Illumina's cutting-edge platforms enable researchers to gain valuable insights into human health and disease, plant and animal genomics, and forensic genomics. With a global presence and a solid track record of delivering high-quality genomic tools, Illumina continues to make significant contributions to the scientific community and shape the future of genomic research.

Illumina Inc has achieved numerous significant milestones. The company revolutionized genetic analysis by developing high-throughput DNA sequencing technologies. It introduced the first commercially available sequencing system, the Genome Analyzer, enabling unprecedented advancements in genomics research. Illumina's innovative technologies have played a pivotal role in driving breakthrough discoveries in fields like cancer research, rare disease diagnosis, and agriculture. The company's contributions have been recognized globally, and it has received various awards and recognitions for its exceptional products and services. Through continuous innovation and strategic collaborations, Illumina Inc remains at the forefront of genomics, continually expanding the boundaries of scientific knowledge.

Illumina Inc is primarily present in various countries and regions worldwide. With its global presence, Illumina serves customers and conducts business operations in North America, Europe, Asia Pacific, and Latin America. The company's headquarters are located in San Diego, California, United States. Illumina has established offices, manufacturing facilities, and collaborations across different nations, including but not limited to the United Kingdom, Germany, Australia, China, Japan, and Brazil. Through its expansive reach and network, Illumina continues to contribute to advancements in genomic research and personalized medicine on a global scale.

Illumina Inc represents values of advancing genomics and enabling researchers to unlock the power of the genome. With a strong corporate philosophy focused on innovation, collaboration, and customer-centricity, Illumina is committed to transforming human health by developing breakthrough technologies in genetic sequencing and analysis. By providing cutting-edge solutions, Illumina empowers scientists and healthcare professionals worldwide to make groundbreaking discoveries and personalized medicine advancements. As a leader in genomics, Illumina Inc strives to drive scientific and clinical progress, ultimately improving lives and shaping the future of genomic medicine.

Analyytikot asettavat tällä hetkellä Illumina-osakkeelle keskimääräisen tavoitehinnan 200,14 USD (mediaani: 210,00 USD), mikä merkitsee −22,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 28 analyytikkoarvioon.

Illumina Analyytikkojen kursstavoitteet 2026

28 analyytikkoa arvioi tällä hetkellä Illumina-osaketta: 16 suosittaa ostoa, 9 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Illumina-yhtiöltä 4,62 Mrd. USD liikevaihtoa ja 5,42 USD osakekohtaista tulosta.

Illumina Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Illumina-osake noteerataan hintaan 231,06 EUR (259,73 USD).

Illumina-osake (ILMN) on listattuna 10 pörssissä, muun muassa: NASDAQ (ILMN), London (0J8Z.L), SIX (Zürich) (ILUCHF.SW), XETRA (ILU.DE), Frankfurt (ILU.F), München (ILU.MU), Düsseldorf (ILU.DU), Wien (ILMN.VI).

Illumina Inc. is a US company specializing in the field of genomics research. It was founded in 1998 by four biochemists and is headquartered in San Diego, California. Illumina is positioned as a leading provider of technologies for DNA and RNA sequencing. The company has five core business areas: genomics, oncology, reproductive and gynecology, agriculture, and forensics. Each of these areas has its own range of products and services. The genomics area is Illumina's largest business area and includes a wide range of solutions for DNA sequencing. These include both devices and software solutions for the analysis and interpretation of sequencing data. The oncology business area focuses on the development of diagnostic solutions for cancer. Illumina offers a range of services, including sequencing of tumor and normal tissues to identify genomic changes and make personalized treatment decisions. In the reproductive and gynecology area, Illumina provides solutions for prenatal diagnostics, including sequencing of the fetal genome. The company also has a comprehensive range of products for in vitro fertilization. In the agriculture business, Illumina offers solutions for genomics of livestock and crops. These solutions can be used for breeding livestock and crops to improve their productivity and health. In the forensics area, Illumina provides solutions for the identification and analysis of DNA traces. These solutions can be used for forensic investigations, identification of individuals, and monitoring of animal populations. Some of Illumina's most well-known products are the HiSeq and MiSeq sequencers, which are used for high-throughput sequencing. There are also cloud-based analysis solutions for interpreting the data, as well as solutions for quantitative PCR. Illumina has also focused on partnerships with other major companies. It collaborates with Roche, Qiagen, Pacific Biosciences, and Oxford Nanopore Technologies to expand and enhance its products and services. Overall, Illumina specializes in integrating genomics and bioinformatics solutions to improve the health and well-being of humans, animals, and plants. The company is a key player in the biotechnology industry and is expected to usher in a new era of personalized medicine.

odotettu liikevaihto Illumina on 4,62 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Illumina on 835,42 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Illumina:n hinta-voitto-suhde (P/E) on tällä hetkellä 47,88. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Illumina-osakkeen arvostusta.

Illumina:n hinta-myynti-suhde (P/S) on tällä hetkellä 8,65. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Illumina-osakkeen arvostuskennuslukuna.

Illumina:n Eulpool-laatuscore on 4/10.

Illumina:n ISIN on US4523271090. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Illumina:n WKN on 927079. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Illumina:n ticker on ILMN. Tämä pörssinoteeraus käytetään Illumina-osakkeiden kauppaan pörssissä.